Oil and Gas Storage Service Industry to Benefit from Increasing Capital Investment in the U.S., Says Esticast Research & Consulting

Jan 08, 2018 12:20 pm UTC| Business

PUNE, India, Jan. 08, 2018 -- The global oil and gas storage service market was valued at $8.42 billion in 2016, and is projected to reach $10.38 billion by 2022, growing at a CAGR of 2.6% from 2017 to 2024. In 2016,...

Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint Inhibitors

Jan 08, 2018 12:15 pm UTC| Business

· CA4P and checkpoint inhibitor combination nearly doubles amount of tumor necrosis SOUTH SAN FRANCISCO, Calif., Jan. 08, 2018 -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing...

Global Drug Discovery Informatics Market 2017-2022 - Rising R&D Expenditure / Increasing Focus On Drug Discovery / Need To Control Drug Discovery And Development Costs

Jan 08, 2018 12:08 pm UTC| Business

Dublin, Jan. 08, 2018 -- The "Drug Discovery Informatics Market by Function, Solution and End User - Global Forecast to 2022" report has been added to Research and Markets' offering. The global drug...

Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments

Jan 08, 2018 12:05 pm UTC| Business

-- Increases KRYSTEXXA® (pegloticase injection) Estimated Peak Annual Net Sales to more than $750 Million ---- Increases Teprotumumab Estimated Peak Annual Net Sales to more than $750 Million ---- Confirms Expectation of...

Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs

Jan 08, 2018 12:02 pm UTC| Business

  Press ReleaseSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs Companies also announce submission of dupilumab...

Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value

Jan 08, 2018 12:02 pm UTC| Business

- Ivosidenib NDA for IDH1m R/R AML Submitted in December for Priority Review; Multiple Pivotal Trials Ongoing or Planned for Ivosidenib in Frontline AML and Solid Tumors Including 4Q 2018 Initiation of Phase 3 Trial with...

Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis

Jan 08, 2018 12:02 pm UTC| Business

–100% (three out of three) of patients have now met the primary endpoint in achieving ≥ 50% clinical response with MAT2203 – – Study has met predetermined statistical endpoint for success – – All patients have elected...